References
- Andersen AD, Binzer M, Stenager E et al. (2017) Cerebrospinal fluid biomarkers for Parkinson’s disease: a systematic review. Acta Neurol Scand 135:34–56. https://doi.org/10.1111/ane.12590
- Carvalho C, Correia SC, Cardoso S et al. (2015) The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases. Expert Rev Neurother 15:867–884. https://doi.org/10.1586/14737175.2015.1058160
- Caudle WM, Bammler TK, Lin Y et al. (2010) Using “omics” to define pathogenesis and biomarkers of Parkinson’s disease. Expert Rev Neurother 10:925–942. https://doi.org/10.1586/ern.10.54
- Chaturvedi RK, Beal MF (2013) Mitochondria targeted therapeutic approaches in Parkinson’s and Huntington’s diseases. Mol Cell Neurosci 55:101–114. https://doi.org/10.1016/j.mcn.2012.11.011
- Derkinderen P, Shannon KM, Brundin P (2014) Gut feelings about smoking and coffee in Parkinson’s disease. Mov Disord 29: 976–979. https://doi.org/10.1002/mds.25882
- Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis 3:461–491. https://doi.org/10.3233/JPD-130230
- Dorsey ER, Sherer T, Okun MS et al. (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8(Suppl. 1):S3–S8. https://doi.org/10.3233/JPD-181474
- Drexler DM, Reily MD, Shipkova PA (2011) Advances in mass spectrometry applied to pharmaceutical metabolomics. Anal Bioanal Chem 399:2645–2653. https://doi.org/10.1007/s00216-010-4370-8
- Evans AM, DeHaven CD, Barrett T et al. (2009) Integrated, non-targeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656–6667. https://doi.org/10.1021/ac901536h
- Gelpi E, Navarro-Otano J, Tolosa E et al. (2014) Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 29:1010–1018. https://doi.org/10.1002/mds.25776
- Graham SF, Rey NL, Yilmaz A et al. (2018) Biochemical profiling of the brain and blood metabolome in a mouse model of prodromal Parkinson’s disease reveals distinct metabolic profiles. J Proteome Res 17:2460–2469. https://doi.org/10.1021/acs.jproteome.8b00224
- Guo L, Milburn MV, Ryals JA et al. (2015) Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Soc U S A 112:E4901–E4910. https://doi.org/10.1073/pnas.1508425112
- Hall S, Surova Y, Öhrfelt A et al. (2015) CSF biomarkers and clinical progression of Parkinson disease. Neurology 84:57–63. https:// doi.org/10.1212/WNL.0000000000001098
- Hiller K, Hangebrauk J, Jäger C et al. (2009) MetaboliteDetector: comprehensive analysis tool for targeted and nontargeted GC/ MS based metabolome analysis. Anal Chem 81:3429–3439. https://doi.org/10.1021/ac802689c
- Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson’s disease: the role of glial cells. J Pharmacol Sci 144:151–164. https://doi.org/10.1016/j.jphs.2020.07.011
- Kozioł A, Pupek M, Lewandowski Ł (2023) Application of metabolomics in diagnostics and differentiation of meningitis: a narrative review with a critical approach to the literature. Biomed Pharmacother 168:115685. https://doi.org/10.1016/j.biopha.2023.115685
- Kumari S, Kumaran SS, Goyal V et al. (2020a) Metabolomic analysis of serum using proton NMR in 6-OHDA experimental PD model and patients with PD. Neurochem Int 134:104670. https://doi.org/10.1016/j.neuint.2020.104670
- Kumari S, Kumaran SS, Goyal V et al. (2020b) Identification of potential urine biomarkers in idiopathic Parkinson’s disease using NMR. Clin Chim Acta 510:442–449. https://doi.org/10.1016/j.cca.2020.08.005
- Lawton KA, Berger A, Mitchell M et al. (2008) Analysis of the adult human plasma metabolome. Pharmacogenomics 9:383–397. https://doi.org/10.2217/14622416.9.4.383
- Lu Y, Zhang X, Zhao L et al. (2018) Metabolic disturbances in the striatum and substantia Nigra in the onset and progression of MPTP-induced Parkinsonism model. Front Neurosci 12:90. https://doi.org/10.3389/fnins.2018.00090
- Meoni G, Tenori L, Schade S et al. (2022) Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients. NPJ Parkinsons Dis 8:14. https://doi.org/10.1038/s41531-021-00274-8
- Motoi Y, Shimada K, Ishiguro K et al. (2014) Lithium and autophagy. ACS Chem Neurosci 5:434–442. https://doi.org/10.1021/cn500056q
- Page MJ, McKenzie JE, Bossuyt PM et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10:89. https://doi.org/10.1186/s13643-021-01626-4
- Peironcely JE, Reijmers T, Coulier L et al. (2011) Understanding and classifying metobolite space and metabolite-likeness. PLoS One 6:e28966. https://doi.org/10.1371/journal.pone.0028966
- Salek RM, Colebrooke RE, Macintosh R et al. (2008) A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene. Neurochem Res 33:292–300. https://doi.org/10.1007/s11064-007-9542-3
- Shen T, Yue Y, He T et al. (2021) The association between the gut microbiota and Parkinson’s disease, a meta-analysis. Front Aging Neurosci 13:636545. https://doi.org/10.3389/fnagi.2021.636545
- Solana-Manrique C, Sanz FJ, Torregrosa I et al. (2022) Metabolic alterations in a Drosophila model of Parkinson’s disease based on DJ-1 deficiency. Cells 11:331. https://doi.org/10.3390/cells11030331
- Sterne JA, Hernán MA, Reeves BC et al. (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https://doi.org/10.1136/bmj.i4919
- Surguchov A (2022) Biomarkers in Parkinson’s disease. In: Peplow PV, Martinez B, Gennarelli TA (eds) Neurodegenerative diseases biomarkers: towards translating research to clinical practice [Internet]. Springer US, New York, NY, 2022 [cited 2025 Feb 3]. pp. 155–180. https://doi.org/10.1007/978-1-0716-1712-0_7
- Toczylowska B, Zieminska E, Michałowska M et al. (2020) Changes in the metabolic profiles of the serum and putamen in Parkinson’s disease patients – in vitro and in vivo NMR spectroscopy studies. Brain Res 1748:147118. https://doi.org/10.1016/j.brainres.2020.147118
- Vilchez D, Saez I, Dillin A (2014) The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun 5:5659. https://doi.org/10.1038/ncomms6659
- Villeneuve LM, Purnell PR, Boska MD et al. (2016) Early expression of Parkinson’s disease-related mitochondrial abnormalities in PINK1 knockout rats. Mol Neurobiol 53:171–186. https://doi.org/10.1007/s12035-014-8927-y
- Yang W, Hamilton JL, Kopil C et al. (2020b) Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis 6:15. https://doi.org/10.1038/s41531-020-0117-1
- Yang C, Zhang T, Wang W et al. (2020a) Brain-region specific metabolic abnormalities in Parkinson’s disease and levodopa-induced dyskinesia. Front Aging Neurosci 12:75. https://doi.org/10.3389/fnagi.2020.00075
- Zhang Z, Zhang S, Fu P et al. (2019) Roles of glutamate receptors in Parkinson’s disease. Int J Mol Sci 20:4391. https://doi.org/10.3390/ijms20184391
- Zheng H, Zhao L, Xia H et al. (2016) NMR-based metabolomics reveal a recovery from metabolic changes in the striatum of 6-OHDA-induced rats treated with basic fibroblast growth factor. Mol Neurobiol 53:6690–6697. https://doi.org/10.1007/s12035-015-9579-2